TW200517142A - Amorphous, spray-dried powders having a reduced moisture content and a high-long term stability - Google Patents

Amorphous, spray-dried powders having a reduced moisture content and a high-long term stability

Info

Publication number
TW200517142A
TW200517142A TW093125236A TW93125236A TW200517142A TW 200517142 A TW200517142 A TW 200517142A TW 093125236 A TW093125236 A TW 093125236A TW 93125236 A TW93125236 A TW 93125236A TW 200517142 A TW200517142 A TW 200517142A
Authority
TW
Taiwan
Prior art keywords
spray
moisture content
amorphous
long term
term stability
Prior art date
Application number
TW093125236A
Other languages
English (en)
Inventor
Karoline Bechtold-Peters
Wolfgang Friess
Stefanie Schuele
Stefan Bassarab
Patrick Garidel
Torsten Schutz-Fademrecht
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of TW200517142A publication Critical patent/TW200517142A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TW093125236A 2003-08-22 2004-08-20 Amorphous, spray-dried powders having a reduced moisture content and a high-long term stability TW200517142A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10339197A DE10339197A1 (de) 2003-08-22 2003-08-22 Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität

Publications (1)

Publication Number Publication Date
TW200517142A true TW200517142A (en) 2005-06-01

Family

ID=34202048

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093125236A TW200517142A (en) 2003-08-22 2004-08-20 Amorphous, spray-dried powders having a reduced moisture content and a high-long term stability

Country Status (11)

Country Link
US (1) US20070298116A1 (zh)
EP (1) EP1658047B1 (zh)
JP (1) JP2007503380A (zh)
KR (1) KR20070054590A (zh)
AT (1) ATE388688T1 (zh)
CA (1) CA2536319A1 (zh)
DE (2) DE10339197A1 (zh)
DK (1) DK1658047T3 (zh)
ES (1) ES2302021T3 (zh)
TW (1) TW200517142A (zh)
WO (1) WO2005020953A1 (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102006023770A1 (de) * 2006-05-20 2007-11-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treibgasfreie Aerosolformulierung für die Inhalation
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
DE102006030164A1 (de) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
DE102006053375A1 (de) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
PT103743B (pt) * 2007-05-16 2013-01-15 Hovione Farmaciencia S A Processo para preparar derivados de 21-disódio fosfato de pregnanos.
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
MX2010007728A (es) 2008-01-15 2010-12-21 Abbott Gmbh & Co Kg Composiciones proteinicas en polvo y metodos para elaborar las mismas.
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
CA2744655A1 (en) * 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
JP5671001B2 (ja) * 2009-03-26 2015-02-18 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
KR20100123240A (ko) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
UA107097C2 (en) 2009-11-25 2014-11-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Dispenser
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
EP2790681B9 (en) 2011-11-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
DE202013012827U1 (de) * 2012-06-14 2020-02-13 Glycom A/S Verbesserung der Stabilität und Reinheit sowie Erhöhung der Bioverfügbarkeit von menschlichen Milch-Oligosacchariden oder Vorläufern oder Mischungen davon
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
US10195374B2 (en) 2014-05-07 2019-02-05 Boehringer Ingelheim International Gmbh Container, nebulizer and use
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
KR102492824B1 (ko) 2014-05-07 2023-01-30 베링거 인겔하임 인터내셔날 게엠베하 분무기, 표시 디바이스 및 컨테이너
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
CN114404371A (zh) * 2015-12-16 2022-04-29 瑞泽恩制药公司 制造蛋白质微粒的组合物和方法
CN110914284A (zh) * 2017-07-12 2020-03-24 格礼卡姆股份公司 包含中性单糖或寡糖和酸性非碳水化合物组分的无定形混合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
MX9702357A (es) * 1994-09-29 1997-06-28 Andaris Ltd Microparticulas secadas por aspersion como vehiculos terapeuticos.
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
JP2001507702A (ja) * 1996-12-31 2001-06-12 インヘイル・セラピューティックス・システムズ・インコーポレテッド 親水性賦形剤を有する疎水性薬剤の水性懸濁液を噴霧乾燥させる方法およびその方法によって作製された組成物
PT954282E (pt) * 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
EP1107743B1 (en) * 1998-08-25 2007-06-27 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
ATE313318T1 (de) * 1999-10-29 2006-01-15 Nektar Therapeutics Trockenpulverzusammensetzungen mit verbesserter dispersität
GB0004827D0 (en) * 2000-02-29 2000-04-19 Quadrant Holdings Cambridge Compositions
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
EP1289494A2 (en) * 2000-06-08 2003-03-12 Powderject Vaccines, Inc. Powder compositions
ATE355849T1 (de) * 2000-12-21 2007-03-15 Nektar Therapeutics Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
EP1399131A2 (en) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Spray freeze-dried compositions
AU2002366267B2 (en) * 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
CA2480270A1 (en) * 2002-04-03 2003-10-09 Solvay Pharmaceuticals B.V. Stabilized natural cannabinoid formulation
KR20100112206A (ko) * 2002-04-11 2010-10-18 메디뮨 엘엘씨 분무 건조에 의한 생물학적 활성 물질의 보존

Also Published As

Publication number Publication date
DE502004006512D1 (de) 2008-04-24
US20070298116A1 (en) 2007-12-27
JP2007503380A (ja) 2007-02-22
CA2536319A1 (en) 2005-03-10
WO2005020953A1 (de) 2005-03-10
EP1658047A1 (de) 2006-05-24
KR20070054590A (ko) 2007-05-29
EP1658047B1 (de) 2008-03-12
ATE388688T1 (de) 2008-03-15
DE10339197A1 (de) 2005-03-24
ES2302021T3 (es) 2008-07-01
DK1658047T3 (da) 2008-06-16

Similar Documents

Publication Publication Date Title
TW200517142A (en) Amorphous, spray-dried powders having a reduced moisture content and a high-long term stability
WO2004112702A3 (en) Low dose pharmaceutical powders for inhalation
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006133941A3 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
HUP0401250A2 (hu) Aeroszol formájú gyógyászati készítmények és eljárás az előállításukra
AU2728900A (en) Multi-purpose acid compositions
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
WO2005044226A3 (en) Lipid formulations for spontaneous drug encapsulation
MXPA05009629A (es) Composiciones que contienen trospio.
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2008087323A8 (fr) Forme galenique pour l'administration par voie trans-muqueuse de paracetamol
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
WO2005004860A3 (fr) Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
WO2005037256A3 (de) Flüssige zubereitung enthaltend tobramycin
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
DE60111637D1 (de) Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
UA89349C2 (uk) Таблетка без покриття, яка містить оланзапін, та спосіб її одержання
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep